The ischemia‐enhanced myocardial infarction protection‐related lncRNA protects against acute myocardial infarction

Rongzhou Wu, Ting-Ting Wu, Qiaoyu Wang, Youyang Shi, Qianqian Dong, Xing Rong, Meiting Chen, Zhiyu He, Yu Fu, Lei Liu, Shuai Shao, Xueqiang Guan, Chunxiang ZhangMedComm 2024 · DOI

TL;DR

Researchers have identified a novel long non-coding RNA (lncRNA) called MIPRL that plays a protective role against acute myocardial infarction (AMI). MIPRL enhances the stability of HSPB8 mRNA, leading to increased HSPB8 protein levels, which in turn reduces cardiomyocyte apoptosis and mitigates cardiac damage after AMI. This discovery opens up potential new therapeutic avenues for treating heart disease.

What Problem Does This Paper Address?

Acute myocardial infarction (AMI), commonly known as a heart attack, is a leading cause of death and disability worldwide. Despite advancements in treatment, our understanding of the molecular mechanisms underlying AMI and the development of effective therapies remains incomplete. Specifically, the role of non-coding RNAs (ncRNAs), a class of RNA molecules that don't code for proteins but have crucial regulatory functions, in the context of AMI is an active area of research. While some ncRNAs have been implicated in various diseases, many remain uncharacterized, and their specific roles in cardiac injury are not fully understood. This paper aims to investigate the function of a lncRNA, RP11-64B16.4, which was found to be highly expressed in ischemic human hearts, and to determine its potential protective role in AMI.

Methods

The study employed a multi-faceted approach to investigate MIPRL's role in AMI:

  • Expression Analysis: Quantitative real-time PCR (qRT-PCR) was used to measure MIPRL expression in human and mouse cardiomyocytes under hypoxia, and in mouse hearts following AMI.
  • Genetic Manipulation: MIPRL knockout (MIPRL-/-) mice were generated using CRISPR/Cas9 technology to assess the consequences of MIPRL deficiency. Adenovirus-mediated overexpression of MIPRL (Ad-MIPRL) and knockdown of HSPB8 (Ad-HSPB8 shRNA) were used for rescue and mechanistic studies.
  • In Vivo Models: The mouse model of AMI was established by ligating the left anterior descending (LAD) artery.
  • Cardiac Function Assessment: Echocardiography was performed to evaluate left ventricular ejection fraction (LVEF), left ventricular fraction shortening (LVFS), and left ventricular internal dimensions (LVIDd, LVIDs).
  • Histological Analysis: TTC staining was used to quantify infarct size, and Masson trichrome staining was employed to assess cardiac fibrosis.
  • Apoptosis Assays: TUNEL staining was used to detect apoptotic cells in heart tissues and cultured cardiomyocytes. Western blotting was used to measure the expression of apoptosis-related proteins like cleaved caspase-3 and Bax.
  • Mechanistic Studies: RNA fluorescence in situ hybridization (RNA-FISH) and double RNA-FISH were used to determine MIPRL's subcellular localization and its co-localization with HSPB8 mRNA. RNA-RNA pull-down assays were conducted to confirm direct binding between MIPRL and HSPB8 mRNA. mRNA stability assays using Actinomycin D were performed to assess the impact of MIPRL on HSPB8 mRNA degradation.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • MIPRL as a Protective Factor: The study establishes MIPRL as a lncRNA that actively protects against cardiac damage during AMI. Its expression is upregulated in response to ischemic stress, suggesting an endogenous protective mechanism.
  • Conserved Function: The finding that MIPRL is conserved between humans and mice is crucial, validating the use of mouse models for studying human cardiac diseases and suggesting a conserved biological role.
  • HSPB8 as a Key Downstream Target: The identification of Heat Shock Protein Beta-8 (HSPB8) as a direct target of MIPRL is a significant mechanistic insight. This connection explains how MIPRL exerts its protective effects.
  • mRNA Stability Regulation: The novel mechanism by which MIPRL enhances HSPB8 expression – by increasing the stability of HSPB8 mRNA – is a key finding. This highlights a sophisticated regulatory strategy employed by lncRNAs.
  • Therapeutic Potential: The demonstration that MIPRL can reverse AMI-induced damage in knockout models strongly suggests its potential as a therapeutic target for heart disease.

Key Results

  • Increased MIPRL Expression: MIPRL expression was significantly increased in cardiomyocytes under hypoxia and in infarcted mouse hearts after AMI.
  • MIPRL Deficiency Exacerbates AMI: MIPRL knockout mice exhibited larger infarct sizes, impaired cardiac function (reduced LVEF and LVFS), and increased cardiac fibrosis compared to wild-type controls after AMI.
  • MIPRL Re-expression Rescues Damage: Overexpression of MIPRL via adenovirus in MIPRL knockout mice reversed the adverse effects of MIPRL deficiency, restoring cardiac function and reducing fibrosis.
  • MIPRL Reduces Apoptosis: MIPRL knockout mice showed increased levels of apoptotic markers (cleaved caspase-3 and Bax) in heart tissues and cardiomyocytes. MIPRL re-expression attenuated this apoptosis.
  • HSPB8 is Essential for MIPRL's Effect: Knockdown of HSPB8 abrogated the protective effects of MIPRL on cardiomyocyte apoptosis and cardiac function after AMI.
  • MIPRL Stabilizes HSPB8 mRNA: MIPRL was found to bind to HSPB8 mRNA, leading to increased stability and thus higher HSPB8 protein levels.

Limitations and Future Work

  • Autophagy and Necrosis: While the study briefly touched upon MIPRL's potential effects on autophagy and necrosis, a more in-depth investigation into these mechanisms is warranted.
  • Detailed Mechanism of Mitophagy: The paper suggests that MIPRL might have effects on mitophagy, but the precise mechanisms require further exploration.
  • Clinical Translation: While MIPRL shows therapeutic promise, further studies are needed to assess its efficacy and safety in more complex preclinical models and eventually in clinical trials.
  • Other Potential Targets: The study focused on HSPB8, but it's possible MIPRL may have other targets that contribute to its cardioprotective effects.
  • Delivery Methods: Optimizing the delivery of MIPRL for therapeutic purposes, especially in a clinical setting, will be a critical area for future research.

Summary updated

Abstract

Long non-coding RNA RP11-64B16.4 (<b>m</b>yocardial <b>i</b>nfarction <b>p</b>rotection-<b>r</b>elated <b>l</b>ncRNA [MIPRL]) is among the most abundant and the most upregulated lncRNAs in ischemic human hearts. However, its role in ischemic heart disease is unknown. We found MIPRL was conserved between human and mouse and its expression was increased in mouse hearts after acute myocardial infarction (AMI) and in cultured human and mouse cardiomyocytes after hypoxia. The infarcted size, cardiac cell apoptosis, cardiac dysfunction, and cardiac fibrosis were aggravated in MIPRL knockout mice after AMI. The above adverse results could be reversed by re-expression of MIPRL via adenovirus expressing MIPRL. Both in vitro and in vivo, we identified that heat shock protein beta-8 (HSPB8) was a target gene of MIPRL, which was involved in MIPRL-mediated anti-apoptotic effects on cardiomyocytes. We further discovered that MIPRL could combine with the messenger RNA (mRNA) of HSPB8 and increase its expression in cardiomyocytes by enhancing the stability of HSPB8 mRNA. In summary, we have found for the first time that the ischemia-enhanced lncRNA MIPRL protects against AMI via its target gene HSPB8. MIPRL might be a novel promising therapeutic target for ischemic heart diseases such as AMI.
BibTeX
@inproceedings{wu2024ischemiaenhanced,
  author = {Rongzhou Wu and Ting-Ting Wu and Qiaoyu Wang and Youyang Shi and Qianqian Dong and Xing Rong and Meiting Chen and Zhiyu He and Yu Fu and Lei Liu and Shuai Shao and Xueqiang Guan and Chunxiang Zhang},
  title = {{The ischemia‐enhanced myocardial infarction protection‐related lncRNA protects against acute myocardial infarction}},
  booktitle = {MedComm},
  year = {2024},
  doi = {10.1002/mco2.632},
}
Figure